A Double-blind Randomized Single-center Trial of Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation.
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Both
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Trial Information
A Double-blind Randomized Single-center Trial of Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation.
Inclusion Criteria:
- Grade II to IV acute GVHD after SCT
Exclusion Criteria:
- Known allergy to basilixmab
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Outcome Measure:
Resolution of GVHD by Day 12
Outcome Time Frame:
12 days
Principal Investigator
Lawrence SY Ma, Dr
Investigator Role:
Principal Investigator
Investigator Affiliation:
Department of Medicine/ Haematology and Oncology, Queen Mary Hospital
Authority:
Hong Kong: Ethics Committee
Study ID:
UW 03-312 T312
NCT ID:
NCT00563108
Start Date:
June 2004
Completion Date:
December 2008
Related Keywords:
- Graft Vs Host Disease
- Hematopoietic Stem Cell Transplantation
- Acute graft-versus-host disease post allogeneic stem cell transplantation
- Graft vs Host Disease
Name | Location |
|---|
